Literature DB >> 26332553

Forbidden and Permitted Statements about Medications--Loosening the Rules.

Jerry Avorn, Ameet Sarpatwari, Aaron S Kesselheim.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 26332553     DOI： 10.1056/NEJMhle1506365

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  4 in total

1.  Digital Direct-to-Consumer Advertising: A Perfect Storm of Rapid Evolution and Stagnant Regulation Comment on "Trouble Spots in Online Direct-to-Consumer Prescription Drug Promotion: A Content Analysis of FDA Warning Letters".

Authors:  Tim K Mackey
Journal:  Int J Health Policy Manag       Date:  2016-02-03

2.  Unhealthy marketing of pharmaceutical products: An international public health concern.

Authors:  Shai Mulinari
Journal:  J Public Health Policy       Date:  2016-02-25       Impact factor: 2.222

3.  The next forum for unraveling FDA off-label marketing rules: State and federal legislatures.

Authors:  Michael S Sinha; Aaron S Kesselheim
Journal:  PLoS Med       Date:  2018-05-08       Impact factor: 11.069

4.  An Uninformative Truth: The Logic of Amarin's Off-Label Promotion.

Authors:  Spencer Phillips Hey; Aaron S Kesselheim
Journal:  PLoS Med       Date:  2016-03-15       Impact factor: 11.069
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.